Literature DB >> 26592186

An Apoferritin-based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib.

Anchala I Kuruppu1, Lei Zhang2, Hilary Collins1, Lyudmila Turyanska3, Neil R Thomas2, Tracey D Bradshaw1.   

Abstract

Anticancer drug Gefitinib encapsulated within human heavy chain apoferritin by diffusion allows pH-controlled sustained release of cargo. The combination of increased cellular uptake, and potent and enhanced antitumor activity against the HER2 overexpressing SKBR3 cell line compared to Gefitinib alone, makes it a promising carrier for delivery of drugs to tumor sites.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Gefitinib; apoferritin; breast cancer; drug delivery; nanoparticles

Mesh：

Substances：

Year:  2015        PMID： 26592186     DOI： 10.1002/adhm.201500389

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN： 2192-2640            Impact factor:   9.933


  13 in total

1.  Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics.

Authors:  Brian Madajewski; Feng Chen; Barney Yoo; Melik Z Turker; Ulrich Wiesner; Michelle S Bradbury; Cameron Brennan; Kai Ma; Li Zhang; Pei-Ming Chen; Rupa Juthani; Virginia Aragon-Sanabria; Mithat Gonen; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2020-07-28       Impact factor: 12.531

Review 2.  Nanocaged platforms: modification, drug delivery and nanotoxicity. Opening synthetic cages to release the tiger.

Authors:  Mahdi Karimi; Parham Sahandi Zangabad; Fatemeh Mehdizadeh; Hedieh Malekzad; Alireza Ghasemi; Sajad Bahrami; Hossein Zare; Mohsen Moghoofei; Amin Hekmatmanesh; Michael R Hamblin
Journal:  Nanoscale       Date:  2017-01-26       Impact factor: 7.790

Review 3.  Bioengineered Ferritin Nanocarriers for Cancer Therapy.

Authors:  Xuanrong Sun; Yulu Hong; Yubei Gong; Shanshan Zheng; Dehui Xie
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

4.  Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs.

Authors:  Claudia Karnthaler-Benbakka; Diana Groza; Bettina Koblmüller; Alessio Terenzi; Katharina Holste; Melanie Haider; Dina Baier; Walter Berger; Petra Heffeter; Christian R Kowol; Bernhard K Keppler
Journal:  ChemMedChem       Date:  2016-10-05       Impact factor: 3.466

5.  Development of novel apoferritin formulations for antitumour benzothiazoles.

Authors:  Alastair F Breen; Geoffrey Wells; Lyudmila Turyanska; Tracey D Bradshaw
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-16

6.  Listeria innocua Dps as a nanoplatform for bioluminescence based photodynamic therapy utilizing Gaussia princeps luciferase and zinc protoporphyrin IX.

Authors:  Ali W Al-Ani; Lei Zhang; Lenny Ferreira; Lyudmila Turyanska; Tracey D Bradshaw; Neil R Thomas
Journal:  Nanomedicine       Date:  2019-04-29       Impact factor: 5.307

7.  Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib.

Authors:  Kateřina Jáklová; Tereza Feglarová; Simona Rex; Zbyněk Heger; Tomáš Eckschlager; Jan Hraběta; Petr Hodek; Matúš Kolárik; Radek Indra
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

8.  Mechanism Study of Thermally Induced Anti-Tumor Drug Loading to Engineered Human Heavy-Chain Ferritin Nanocages Aided by Computational Analysis.

Authors:  Shuang Yin; Yongdong Liu; Sheng Dai; Bingyang Zhang; Yiran Qu; Yao Zhang; Woo-Seok Choe; Jingxiu Bi
Journal:  Biosensors (Basel)       Date:  2021-11-11

9.  Serum ferritin and primary lung cancer.

Authors:  Zhongqing Chen; Bo Zhu; Chao Ou; Yuxuan Li
Journal:  Oncotarget       Date:  2017-10-04

Review 10.  Ferritins as natural and artificial nanozymes for theranostics.

Authors:  Bing Jiang; Long Fang; Kongming Wu; Xiyun Yan; Kelong Fan
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.